Teva Pharm Q1 profit down, cuts 2022 revenue outlook

[May 03, 2022]    JERUSALEM (Reuters) - Israel-based Teva Pharmaceutical Industries reported as expected first-quarter profit and trimmed 2022 revenue estimates due to currency fluctuations.

The world's largest generic drugmaker said on Tuesday it earned 55 cents per diluted share excluding one-time items in the January-March period, down from 63 cents a share a year earlier. Revenue fell 8% to $3.66 billion.

Analysts had forecast Teva would earn 55 cents a share ex-items on revenue of $3.76 billion, according to I/B/E/S data from Refinitiv.

Teva lowered its 2022 revenue estimate to $15.4-$16.0 billion from $15.6-$16.2 billion, after revenue of $15.9 billion in 2021. It previously projected 2022 adjusted EPS of $2.40-$2.60, versus $2.58 last year.

(Reporting by Steven Scheer; Editing by Ari Rabinovitch)

[© 2022 Thomson Reuters. All rights reserved.]
This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.